Living Longer, Healthier Lives: The Power of Cardiovascular Health Metrics
Have you ever wondered if your heart health could influence how long you live without experiencing cardiovascular diseases (CVDs)? A recent study aimed to answer this question by examining the association between cardiovascular health (CVH) metrics and life expectancy in individuals free of CVD events. The study was based on the concept of predictive, preventive, and personalized medicine (PPPM/3PM), which aims to tailor medical treatment to individual patient needs.
The study followed 92,795 participants over a median period of 13 years. The researchers found that maintaining ideal CVH could significantly reduce the risk of developing CVD events and premature mortality. Specifically, women with ideal CVH at age 35 lived about 5 years longer without CVD events compared to those with poor CVH metrics. For men, the difference was even more pronounced, with ideal CVH associated with nearly 7 years longer life expectancy free of CVD events.
In conclusion, maintaining an ideal CVH status can lead to a lower risk of premature death and a longer life expectancy, both in the general population and in patients with CVD. This suggests that promoting a higher CVH score or ideal CVH status could reduce the burden of CVD events and extend disease-free life expectancy. This approach aligns with the concept of PPPM/3PM, offering a cost-effective strategy for personalized medicine for potential CVD patients.
Article Information
Ideal cardiovascular health metrics and life expectancy free of cardiovascular diseases: a prospective cohort study
Published on EPMA Journal. Qiuyue Tian et al.
Abstract
Objectives: Whether cardiovascular health (CVH) metrics impact longevity with and without cardiovascular diseases (CVDs) has not been well established. This study aimed to investigate the association between CVH metrics and life expectancy in participants free of CVD events. We hypothesized that ideal CVH status was associated with increased life expectancy and assessed the effect of CVH status as a prevention target of longevity in the framework of predictive, preventive, and personalized medicine (PPPM/3PM).
Methods: A total of 92,795 participants in the Kailuan study were examined and thereafter followed up until 2020. We considered three transitions (from non-CVD events to incident CVD events, from non-CVD events to mortality, and from CVD events to mortality). The multistate lifetable method was applied to estimate the life expectancy.
Results: During a median follow-up of 13 years, 12,541 (13.51%) deaths occurred. Compared with poor CVH, ideal CVH attenuated the risk of incident CVD events and mortality without CVD events by approximately 58% and 27%, respectively. Women with ideal CVH at age 35 had a 5.00 (3.23-6.77) year longer life expectancy free of CVD events than did women with poor CVH metrics. Among men, ideal CVH was associated with a 6.74 (5.55-7.93) year longer life expectancy free of CVD events.
Conclusion: An ideal CVH status is associated with a lower risk of premature mortality and a longer life expectancy, either in the general population or in CVD patients, which are cost-effective ways for personalized medicine of potential CVD patients. Our findings suggest that the promotion of a higher CVH score or ideal CVH status would result in reduced burdens of CVD events and extended disease-free life expectancy, which offered an accurate prediction for primary care following the concept of PPPM/3PM.
Bring preventive care to your clinic
© Longevity Artificial Intelligence. All rights reserved.